ClinicalTrials.gg
CompletedNCT01870999Updated Jan 22, 2014Results posted

A Multiple Dose Safety, Tolerability and Pharmacokinetics Study in Adult Patients With Schizophrenia Following Administration of Aripiprazole IM Depot

A Phase 1 interventional study of aripiprazole IM depot and aripiprazole tablets in Schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 7 sites in United States. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2014-01-22.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
41
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 126 studies testing aripiprazole in Schizophrenia — 4 open to participants now, 4 under way, 1 of them phase 3. Aripiprazole · Schizophrenia.

Enrollment
98th of 125
41 · median 130
Started
2007
with 6 others
Phase 1
13 of 126
none open now
Registered
78th of 126
by date
Lead sponsor
44 of 126
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 126 studies testing aripiprazole in Schizophrenia, this one is the 98th largest by enrollment of the 125 interventional ones that give a count, is one of 7 that started in 2007, is one of 13 in phase 1, and was the 78th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

4 of the 126 studies testing aripiprazole in Schizophrenia are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About aripiprazole

Aripiprazole: first FDA approval 2002 (ABILIFY), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 126 studies testing aripiprazole in Schizophrenia, or all of them as a file.
02

Study summary

This study will evaluate the safety, tolerability, efficacy and pharmacokinetics of aripiprazole intramuscular (IM) depot multiple doses every 4 weeks in adult patients with schizophrenia.

03

Conditions studied

  • Schizophrenia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • diagnosis of schizophrenia as defined by , Fourth Edition (DSM-IV) criteria
  • good physical health as determined by normal medical history, clinical laboratory results, (ECGs) and physical examinations
  • ability to provide and/or consent from a legally acceptable representation
  • (BMI) of 18 to 35 kg/m\^2

Exclusion criteria

Exclusion Criteria:

  • sexually active males and females of who are not practicing double barrier or are not abstinent during the study plus 30 days for female or 90 days for males following the last dose of medication
  • history of drug or alcohol abuse within 6 months and/or positive urine drug screen
  • participants who consume alcohol beverages routinely
  • participants who consume alcohol beverages during the screening period
  • use of any antipsychotic medication, other prohibited psychotropic medication, and any cytochrome P450 2D6 (CYP2D6) and cytochrome P450 3A4 () inhibitors or CYP3A4 inducers within 14 days
  • use of any prescription medication unless approved by Medical Monitor or Study Director
  • history of current hepatitis or carrier of (Hepatitis B surface antigen) and/or Virus antibodies (anti-HCV)
  • females who are pregnant or lactating
  • participants who have participated in any clinical trial involving a psychotropic medication within one month prior to enrollment; participants who have participated in a previous IM Depot study within the last 1 year; patients who have previously enrolled and received study medication in an aripiprazole IM Depot clinical trial
  • donation of blood or plasma to a blood bank or in a clinical study (except a screening visit)within 30 days prior to enrollment
  • any major surgery within 30 days prior to enrollment
  • blood transfusion within 30 days prior to enrollment
  • evidence of organ dysfunction or any deviation from normal in the physical, electrocardiographic, or clinical laboratory examinations
  • patient represents a significant risk of committing suicide based on history
  • patients currently in an acute relapse
  • patients with Axis I () diagnosis of schizoaffective or bipolar disorder
  • patients who are considered treatment-resistant to antipsychotic medication
  • patients with a history of neuroleptic malignant syndrome
  • any other sound medical reason as determined by the clinical investigator
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
41 participants (actual)

Study arms

  • Experimental
    400 mg Aripiprazole IM Depot

    400 mg aripiprazole IM (intramuscular) depot intramuscular injection once every 4 weeks for 5 months. All participants were on a stable dose of 10 mg aripiprazole tablets once daily in the morning for at least 14 days prior to randomization and continued 10 mg aripiprazole tablets once daily on days 1 to 14.

    Drug: aripiprazole IM depot · Drug: aripiprazole tablets

  • Experimental
    300 mg Aripiprazole IM Depot

    300 mg aripiprazole IM depot intramuscular injection once every 4 weeks for 5 months. All participants were on a stable dose of 10 mg aripiprazole tablets once daily in the morning for at least 14 days prior to randomization and continued 10 mg aripiprazole tablets once daily on days 1 to 14.

    Drug: aripiprazole IM depot · Drug: aripiprazole tablets

  • Experimental
    200 mg Aripiprazole IM depot

    200 mg aripiprazole IM depot intramuscular injection once every 4 weeks for 5 months. All participants were on a stable dose of 10 mg aripiprazole tablets once daily in the morning for at least 14 days prior to randomization and continued 10 mg aripiprazole tablets once daily on days 1 to 14.

    Drug: aripiprazole IM depot · Drug: aripiprazole tablets

Interventions

  • Aripiprazole IM depot supplied as 200 mg or 400 mg vials of lyophilized aripiprazole powder to prepare for IM injection.

  • Aripiprazole tablets 10 mg once daily in the morning for 14 days.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events as a Measure of Safety

    Safety and tolerability was assessed by the number of participants with adverse events (AE). An AE was defined as any new medical problem, or exacerbation of an existing problem, experienced by a subject while enrolled in the study, whether or not it was considered drug-related by the investigator. Abnormal laboratory test findings were considered AEs if, in the opinion of the investigator, they represented an abnormal (ie, clinically significant) change from baseline for that individual participant.

    Time frame: 7 Months

  2. Aripiprazole Maximum Steady State Plasma Concentration (Css,Max)

    Blood samples were collected for pharmacokinetic parameters pre-dose and 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 168, 264, 336, 504, 672, 1008 and 1344 hours post-dose and were analyzed for aripiprazole. Values for Css,max were determined directly from the observed data during the dosing interval (0-1344 hours) after the fifth monthly injection.

    Time frame: Pre-dose and 1 to 1344 hours post-dose at Month 5

  3. Aripiprazole Minimum Steady State Plasma Concentration (Css,Min)

    Blood samples were collected for pharmacokinetic parameters pre-dose and 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 168, 264, 336, 504, 672, 1008 and 1344 hours post-dose and were analyzed for aripiprazole. Values for Css,min were determined directly from the observed data at 672 hours after the fifth monthly injection.

    Time frame: 672 hours post-dose at Month 5

  4. Aripiprazole Area Under the Concentration-time Curve at Steady-state (AUCτ)

    Blood samples were collected for pharmacokinetic parameters pre-dose and 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 168, 264, 336, 504, 672, 1008 and 1344 hours post-dose and were analyzed for aripiprazole. Values of AUCτ were estimated using the linear trapezoidal rule during each dosing interval from 0 to 1344 hours post-dose.

    Time frame: Pre-dose and 1 to 1344 hours post-dose at Month 5

Secondary outcomes

  1. Aripiprazole Maximum (Peak) Plasma Concentration (Tmax)

    Blood samples were collected for pharmacokinetic parameters pre-dose and 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 168, 264, 336, 504, 672, 1008 and 1344 hours post-dose and were analyzed for aripiprazole. Values for tmax were determined directly from the observed data during the dosing interval (0-1344 hours) after the fifth monthly injection.

    Time frame: Pre-dose and 1 to 1344 hours post-dose at Month 5

  2. Aripiprazole Steady-state Plasma Concentration (Css,Avg)

    Blood samples were collected for pharmacokinetic parameters pre-dose and 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 168, 264, 336, 504, 672, 1008 and 1344 hours post-dose and were analyzed for aripiprazole. Values for Css,avg were determined directly from the observed data during the dosing interval (0-1344 hours) after the fifth monthly injection.

    Time frame: Pre-dose and 1 to 1344 hours post-dose at Month 5

  3. Aripiprazole Terminal-phase Elimination Half-life (t1/2,z)

    Blood samples were collected for pharmacokinetic parameters pre-dose and 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 168, 264, 336, 504, 672, 1008 and 1344 hours post-dose and were analyzed for aripiprazole. Values for t1/2,z were determined directly from the observed data during the dosing interval (0-1344 hours) after the fifth monthly injection.

    Time frame: Pre-dose and 1 to 1344 hours post-dose at Month 5

  4. Dehydro-aripiprazole Maximum Steady State Plasma Concentration (Css,Max)

    Blood samples were collected for pharmacokinetic parameters pre-dose and 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 168, 264, 336, 504, 672, 1008 and 1344 hours post-dose and were analyzed for dehydro-aripiprazole. Values for Css,max were determined directly from the observed data during the dosing interval (0-1344 hours) after the fifth monthly injection.

    Time frame: Pre-dose and 1 to 1344 hours post-dose at Month 5

  5. Dehydro-aripiprazole Minimum Steady State Plasma Concentration (Css,Min)

    Blood samples were collected for pharmacokinetic parameters pre-dose and 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 168, 264, 336, 504, 672, 1008 and 1344 hours post-dose and were analyzed for dehydro-aripiprazole. Values for Css,min were determined directly from the observed data during the dosing interval (0-1344 hours) after the fifth monthly injection.

    Time frame: Pre-dose and 1 to 1344 hours post-dose at Month 5

  6. Dehydro-aripiprazole Area Under the Concentration-Time Curve at Steady-State (AUCτ)

    Blood samples were collected for pharmacokinetic parameters pre-dose and 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 168, 264, 336, 504, 672, 1008 and 1344 hours post-dose and were analyzed for dehydro-aripiprazole. Values of AUCτ were estimated using the linear trapezoidal rule during each dosing interval from 0 to 1344 hours post-dose.

    Time frame: Pre-dose and 1 to 1344 hours post-dose at Month 5

  7. Dehydro-aripiprazole Maximum (Peak) Plasma Concentration (Tmax)

    Blood samples were collected for pharmacokinetic parameters pre-dose and 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 168, 264, 336, 504, 672, 1008 and 1344 hours post-dose and were analyzed for dehydro-aripiprazole. Values for tmax were determined directly from the observed data during the dosing interval (0-1344 hours) after the fifth monthly injection.

    Time frame: Pre-dose and 1 to 1344 hours post-dose at Month 5

  8. Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 12 and Week 24

    The PANSS consisted of 3 subscales with a total of 30 symptom constructs each rated on a 7-point scale where 1=absence of symptoms to 7=extremely severe symptoms. The Positive Subscale consisted of 7 positive symptom constructs with a possible subscale score of 7 to 49, the Negative Subscale consisted of 7 negative symptom constructs with a possible subscale score of 7 to 49 and the General Psychopathology Subscale consisted of 16 symptom constructs for a possible subscale score of 16 to 112. The PANSS Total Score ranged from 30 (best) to 210 (worst; indicating more severe symptoms). A Negative change from Baseline indicated improvement.

    Time frame: Baseline, Week 12, Week 24

  9. Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Positive Subscale Scores at Week 12 and Week 24

    The PANSS Positive Subscale consisted of 7 symptom constructs: delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. Severity was rated on a 7-point scale where 1=absence of symptoms to 7=extremely severe symptoms. The total score on the Positive Subscale ranged from 7 to 49 with a higher score indicating more severe symptoms. A Negative change from Baseline indicated improvement.

    Time frame: Baseline, Week 12, Week 24

  10. Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Negative Subscale Scores at Week 12 and Week 24

    The PANSS Negative Subscale consisted of 7 negative symptom constructs: blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking. Severity was rated on a 7-point scale where 1=absence of symptoms to 7=extremely severe symptoms. The total score on the Negative Subscale ranged from 7 to 49 with a higher score indicating more severe symptoms. A negative change from Baseline indicated improvement.

    Time frame: Baseline, Week 12, Week 24

  11. Change From Baseline in the Clinical Global Impression- Severity of Illness Score (CGI-S) at Week 12 and Week 24

    The severity of illness for each participant was rated using the CGI-S scale. The investigator answered the following question: "Considering your total clinical experience with this particular population, how mentally ill is the patient at this time?" using an 8-point scale where 0=not assessed to 7=among the most extremely ill patients. A negative change from Baseline indicated improvement.

    Time frame: Baseline, Week 12, Week 24

  12. Clinical Global Impression-Improvement Scale (CGI-I) at Week 12 and Week 24

    The participant's overall improvement was rated for each participant using the CGI-I scale. The investigator rated the participant's total improvement by answering the following question: "Compared to his/her condition at baseline (prior to randomization), how much has the patient changed?" using an 8-point scale where 0=not assessed, 1=very much improved to 7=very much worse. Lower scores indicated improvement.

    Time frame: Baseline, Week 12, Week 24

  13. Number of Participants Hospitalized for Adverse Event "Worsening Schizophrenia"

    The number of participants hospitalized for the Adverse Event "Worsening Schizophrenia included all participants who were hospitalized for any Adverse Event pertaining to the exacerbation of schizophrenic symptoms.

    Time frame: 7 Months

07

Results

Posted Jan 22, 2014

Participant flow

Participant flow — Overall Study
Milestone400 mg Aripiprazole IM Depot300 mg Aripiprazole IM Depot200 mg Aripiprazole IM Depot
Started141611
Safety population; received study drug141510
Completed1084
Not completed487
Withdrew: Adverse event041
Withdrew: Subject met withdrawal criteria320
Withdrew: Subject withdrawn by investigator100
Withdrew: Withdrawal by subject025
Withdrew: Protocol violation001

Outcome measures

PrimaryNumber of Participants With Adverse Events as a Measure of Safety

Safety and tolerability was assessed by the number of participants with adverse events (AE). An AE was defined as any new medical problem, or exacerbation of an existing problem, experienced by a subject while enrolled in the study, whether or not it was considered drug-related by the investigator. Abnormal laboratory test findings were considered AEs if, in the opinion of the investigator, they represented an abnormal (ie, clinically significant) change from baseline for that individual participant.

Time frame:
7 Months
Reported as:
Number · Participants
Number of Participants With Adverse Events as a Measure of Safety
Participants400 mg Aripiprazole IM Depot300 mg Aripiprazole IM Depot200 mg Aripiprazole IM Depot
Number of Participants With Adverse Events as a Measure of Safety11116
PrimaryAripiprazole Maximum Steady State Plasma Concentration (Css,Max)

Blood samples were collected for pharmacokinetic parameters pre-dose and 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 168, 264, 336, 504, 672, 1008 and 1344 hours post-dose and were analyzed for aripiprazole. Values for Css,max were determined directly from the observed data during the dosing interval (0-1344 hours) after the fifth monthly injection.

Time frame:
Pre-dose and 1 to 1344 hours post-dose at Month 5
Reported as:
Mean · ng/mL
Aripiprazole Maximum Steady State Plasma Concentration (Css,Max)
ng/mL400 mg Aripiprazole IM Depot300 mg Aripiprazole IM Depot200 mg Aripiprazole IM Depot
Aripiprazole Maximum Steady State Plasma Concentration (Css,Max)316 ± 160269 ± 128100 ± 68.4
PrimaryAripiprazole Minimum Steady State Plasma Concentration (Css,Min)

Blood samples were collected for pharmacokinetic parameters pre-dose and 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 168, 264, 336, 504, 672, 1008 and 1344 hours post-dose and were analyzed for aripiprazole. Values for Css,min were determined directly from the observed data at 672 hours after the fifth monthly injection.

Time frame:
672 hours post-dose at Month 5
Reported as:
Mean · ng/mL
Aripiprazole Minimum Steady State Plasma Concentration (Css,Min)
ng/mL400 mg Aripiprazole IM Depot300 mg Aripiprazole IM Depot200 mg Aripiprazole IM Depot
Aripiprazole Minimum Steady State Plasma Concentration (Css,Min)212 ± 113156 ± 67.795.0 ± 86.2
PrimaryAripiprazole Area Under the Concentration-time Curve at Steady-state (AUCτ)

Blood samples were collected for pharmacokinetic parameters pre-dose and 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 168, 264, 336, 504, 672, 1008 and 1344 hours post-dose and were analyzed for aripiprazole. Values of AUCτ were estimated using the linear trapezoidal rule during each dosing interval from 0 to 1344 hours post-dose.

Time frame:
Pre-dose and 1 to 1344 hours post-dose at Month 5
Reported as:
Mean · μg*h/mL
Aripiprazole Area Under the Concentration-time Curve at Steady-state (AUCτ)
μg*h/mL400 mg Aripiprazole IM Depot300 mg Aripiprazole IM Depot200 mg Aripiprazole IM Depot
Aripiprazole Area Under the Concentration-time Curve at Steady-state (AUCτ)163 ± 88.8140 ± 58.454.5 ± 39.4
SecondaryAripiprazole Maximum (Peak) Plasma Concentration (Tmax)

Blood samples were collected for pharmacokinetic parameters pre-dose and 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 168, 264, 336, 504, 672, 1008 and 1344 hours post-dose and were analyzed for aripiprazole. Values for tmax were determined directly from the observed data during the dosing interval (0-1344 hours) after the fifth monthly injection.

Time frame:
Pre-dose and 1 to 1344 hours post-dose at Month 5
Reported as:
Median · Day
Aripiprazole Maximum (Peak) Plasma Concentration (Tmax)
Day400 mg Aripiprazole IM Depot300 mg Aripiprazole IM Depot200 mg Aripiprazole IM Depot
Aripiprazole Maximum (Peak) Plasma Concentration (Tmax)7.1 (3.0 to 11.2)6.5 (0.5 to 21.2)5.0 (4.0 to 27.9)
SecondaryAripiprazole Steady-state Plasma Concentration (Css,Avg)

Blood samples were collected for pharmacokinetic parameters pre-dose and 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 168, 264, 336, 504, 672, 1008 and 1344 hours post-dose and were analyzed for aripiprazole. Values for Css,avg were determined directly from the observed data during the dosing interval (0-1344 hours) after the fifth monthly injection.

Time frame:
Pre-dose and 1 to 1344 hours post-dose at Month 5
Reported as:
Mean · ng/mL
Aripiprazole Steady-state Plasma Concentration (Css,Avg)
ng/mL400 mg Aripiprazole IM Depot300 mg Aripiprazole IM Depot200 mg Aripiprazole IM Depot
Aripiprazole Steady-state Plasma Concentration (Css,Avg)242 ± 132208 ± 87.081.1 ± 58.7
SecondaryAripiprazole Terminal-phase Elimination Half-life (t1/2,z)

Blood samples were collected for pharmacokinetic parameters pre-dose and 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 168, 264, 336, 504, 672, 1008 and 1344 hours post-dose and were analyzed for aripiprazole. Values for t1/2,z were determined directly from the observed data during the dosing interval (0-1344 hours) after the fifth monthly injection.

Time frame:
Pre-dose and 1 to 1344 hours post-dose at Month 5
Reported as:
Mean · Day
Aripiprazole Terminal-phase Elimination Half-life (t1/2,z)
Day400 mg Aripiprazole IM Depot300 mg Aripiprazole IM Depot200 mg Aripiprazole IM Depot
Aripiprazole Terminal-phase Elimination Half-life (t1/2,z)46.5 ± 10.829.9 ± 8.0—
SecondaryDehydro-aripiprazole Maximum Steady State Plasma Concentration (Css,Max)

Blood samples were collected for pharmacokinetic parameters pre-dose and 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 168, 264, 336, 504, 672, 1008 and 1344 hours post-dose and were analyzed for dehydro-aripiprazole. Values for Css,max were determined directly from the observed data during the dosing interval (0-1344 hours) after the fifth monthly injection.

Time frame:
Pre-dose and 1 to 1344 hours post-dose at Month 5
Reported as:
Mean · ng/mL
Dehydro-aripiprazole Maximum Steady State Plasma Concentration (Css,Max)
ng/mL400 mg Aripiprazole IM Depot300 mg Aripiprazole IM Depot200 mg Aripiprazole IM Depot
Dehydro-aripiprazole Maximum Steady State Plasma Concentration (Css,Max)89.4 ± 37.974.7 ± 20.830.3 ± 19.8
SecondaryDehydro-aripiprazole Minimum Steady State Plasma Concentration (Css,Min)

Blood samples were collected for pharmacokinetic parameters pre-dose and 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 168, 264, 336, 504, 672, 1008 and 1344 hours post-dose and were analyzed for dehydro-aripiprazole. Values for Css,min were determined directly from the observed data during the dosing interval (0-1344 hours) after the fifth monthly injection.

Time frame:
Pre-dose and 1 to 1344 hours post-dose at Month 5
Reported as:
Mean · ng/mL
Dehydro-aripiprazole Minimum Steady State Plasma Concentration (Css,Min)
ng/mL400 mg Aripiprazole IM Depot300 mg Aripiprazole IM Depot200 mg Aripiprazole IM Depot
Dehydro-aripiprazole Minimum Steady State Plasma Concentration (Css,Min)64.1 ± 27.054.1 ± 21.126.2 ± 24.7
SecondaryDehydro-aripiprazole Area Under the Concentration-Time Curve at Steady-State (AUCτ)

Blood samples were collected for pharmacokinetic parameters pre-dose and 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 168, 264, 336, 504, 672, 1008 and 1344 hours post-dose and were analyzed for dehydro-aripiprazole. Values of AUCτ were estimated using the linear trapezoidal rule during each dosing interval from 0 to 1344 hours post-dose.

Time frame:
Pre-dose and 1 to 1344 hours post-dose at Month 5
Reported as:
Mean · μg*h/mL
Dehydro-aripiprazole Area Under the Concentration-Time Curve at Steady-State (AUCτ)
μg*h/mL400 mg Aripiprazole IM Depot300 mg Aripiprazole IM Depot200 mg Aripiprazole IM Depot
Dehydro-aripiprazole Area Under the Concentration-Time Curve at Steady-State (AUCτ)47.8 ± 19.138.9 ± 13.214.7 ± 9.47
SecondaryDehydro-aripiprazole Maximum (Peak) Plasma Concentration (Tmax)

Blood samples were collected for pharmacokinetic parameters pre-dose and 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 168, 264, 336, 504, 672, 1008 and 1344 hours post-dose and were analyzed for dehydro-aripiprazole. Values for tmax were determined directly from the observed data during the dosing interval (0-1344 hours) after the fifth monthly injection.

Time frame:
Pre-dose and 1 to 1344 hours post-dose at Month 5
Reported as:
Median · Day
Dehydro-aripiprazole Maximum (Peak) Plasma Concentration (Tmax)
Day400 mg Aripiprazole IM Depot300 mg Aripiprazole IM Depot200 mg Aripiprazole IM Depot
Dehydro-aripiprazole Maximum (Peak) Plasma Concentration (Tmax)6.6 (3.0 to 14.0)12.5 (0.5 to 22.2)5.5 (0.0 to 27.9)
SecondaryChange From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 12 and Week 24

The PANSS consisted of 3 subscales with a total of 30 symptom constructs each rated on a 7-point scale where 1=absence of symptoms to 7=extremely severe symptoms. The Positive Subscale consisted of 7 positive symptom constructs with a possible subscale score of 7 to 49, the Negative Subscale consisted of 7 negative symptom constructs with a possible subscale score of 7 to 49 and the General Psychopathology Subscale consisted of 16 symptom constructs for a possible subscale score of 16 to 112. The PANSS Total Score ranged from 30 (best) to 210 (worst; indicating more severe symptoms). A Negative change from Baseline indicated improvement.

Time frame:
Baseline, Week 12, Week 24
Reported as:
Mean · units on a scale
Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 12 and Week 24
units on a scale400 mg Aripiprazole IM Depot300 mg Aripiprazole IM Depot200 mg Aripiprazole IM Depot
Week 120.0 ± 20.21.1 ± 12.1-1.3 ± 4.8
Week 24-0.8 ± 20.9-1.6 ± 14.1-1.3 ± 5.3
SecondaryChange From Baseline in the Positive and Negative Syndrome Scale (PANSS) Positive Subscale Scores at Week 12 and Week 24

The PANSS Positive Subscale consisted of 7 symptom constructs: delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. Severity was rated on a 7-point scale where 1=absence of symptoms to 7=extremely severe symptoms. The total score on the Positive Subscale ranged from 7 to 49 with a higher score indicating more severe symptoms. A Negative change from Baseline indicated improvement.

Time frame:
Baseline, Week 12, Week 24
Reported as:
Mean · units on a scale
Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Positive Subscale Scores at Week 12 and Week 24
units on a scale400 mg Aripiprazole IM Depot300 mg Aripiprazole IM Depot200 mg Aripiprazole IM Depot
Week 12-1.2 ± 6.11.3 ± 4.0-1.0 ± 1.2
Week 24-1.6 ± 6.10.4 ± 4.5-1.0 ± 1.6
SecondaryChange From Baseline in the Positive and Negative Syndrome Scale (PANSS) Negative Subscale Scores at Week 12 and Week 24

The PANSS Negative Subscale consisted of 7 negative symptom constructs: blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking. Severity was rated on a 7-point scale where 1=absence of symptoms to 7=extremely severe symptoms. The total score on the Negative Subscale ranged from 7 to 49 with a higher score indicating more severe symptoms. A negative change from Baseline indicated improvement.

Time frame:
Baseline, Week 12, Week 24
Reported as:
Mean · units on a scale
Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Negative Subscale Scores at Week 12 and Week 24
units on a scale400 mg Aripiprazole IM Depot300 mg Aripiprazole IM Depot200 mg Aripiprazole IM Depot
Week 121.1 ± 4.40.1 ± 3.20.0 ± 2.0
Week 240.5 ± 4.2-0.1 ± 3.7-0.6 ± 2.0
SecondaryChange From Baseline in the Clinical Global Impression- Severity of Illness Score (CGI-S) at Week 12 and Week 24

The severity of illness for each participant was rated using the CGI-S scale. The investigator answered the following question: "Considering your total clinical experience with this particular population, how mentally ill is the patient at this time?" using an 8-point scale where 0=not assessed to 7=among the most extremely ill patients. A negative change from Baseline indicated improvement.

Time frame:
Baseline, Week 12, Week 24
Reported as:
Mean · units on a scale
Change From Baseline in the Clinical Global Impression- Severity of Illness Score (CGI-S) at Week 12 and Week 24
units on a scale400 mg Aripiprazole IM Depot300 mg Aripiprazole IM Depot200 mg Aripiprazole IM Depot
Week 12-0.1 ± 0.50.0 ± 0.6-0.2 ± 0.4
Week 24-0.1 ± 0.5-0.1 ± 0.7-0.2 ± 0.4
SecondaryClinical Global Impression-Improvement Scale (CGI-I) at Week 12 and Week 24

The participant's overall improvement was rated for each participant using the CGI-I scale. The investigator rated the participant's total improvement by answering the following question: "Compared to his/her condition at baseline (prior to randomization), how much has the patient changed?" using an 8-point scale where 0=not assessed, 1=very much improved to 7=very much worse. Lower scores indicated improvement.

Time frame:
Baseline, Week 12, Week 24
Reported as:
Mean · units on a scale
Clinical Global Impression-Improvement Scale (CGI-I) at Week 12 and Week 24
units on a scale400 mg Aripiprazole IM Depot300 mg Aripiprazole IM Depot200 mg Aripiprazole IM Depot
Week 12 (n=12, 13, 9)3.3 ± 0.93.6 ± 0.83.4 ± 0.7
Week 243.7 ± 1.03.4 ± 0.73.7 ± 0.7
SecondaryNumber of Participants Hospitalized for Adverse Event "Worsening Schizophrenia"

The number of participants hospitalized for the Adverse Event "Worsening Schizophrenia included all participants who were hospitalized for any Adverse Event pertaining to the exacerbation of schizophrenic symptoms.

Time frame:
7 Months
Reported as:
Number · Participants
Number of Participants Hospitalized for Adverse Event "Worsening Schizophrenia"
Participants400 mg Aripiprazole IM Depot300 mg Aripiprazole IM Depot200 mg Aripiprazole IM Depot
Number of Participants Hospitalized for Adverse Event "Worsening Schizophrenia"010

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
400 mg Aripiprazole IM Depot—0/14 (0%)9/14 (64.3%)
300 mg Aripiprazole IM Depot—3/15 (20%)10/15 (66.7%)
200 mg Aripiprazole IM Depot—0/10 (0%)6/10 (60%)
Most frequent serious events
Most frequent serious events
Event400 mg Aripiprazole IM Depot300 mg Aripiprazole IM Depot200 mg Aripiprazole IM Depot
Chest PainGeneral disorders0/141/150/10
Diabetic ketoacidosisMetabolism and nutrition disorders0/141/150/10
Psychotic disorderPsychiatric disorders0/141/150/10
SchizophreniaPsychiatric disorders0/141/150/10
Most frequent other events
Showing 10 of 64
Most frequent other events
Event400 mg Aripiprazole IM Depot300 mg Aripiprazole IM Depot200 mg Aripiprazole IM Depot
Injection site painGeneral disorders4/140/150/10
TremorNervous system disorders3/141/150/10
HeadacheNervous system disorders1/140/152/10
VomitingGastrointestinal disorders2/142/150/10
NasopharyngitisInfections and infestations2/141/150/10
Upper respiratory tract infectionInfections and infestations2/141/151/10
Muscle strainInjury, poisoning and procedural complications2/140/150/10
Musculoskeletal stiffnessMusculoskeletal and connective tissue disorders2/140/150/10
SedationNervous system disorders2/140/150/10
RashSkin and subcutaneous tissue disorders2/140/150/10

Baseline characteristics

All participants randomized

Age, Continuous
Age, Continuous(years)400 mg Aripiprazole IM Depot300 mg Aripiprazole IM Depot200 mg Aripiprazole IM DepotTotal
Mean46.8 ± 9.243.3 ± 9.646.0 ± 12.745.2 ± 10.3
Sex: Female, Male
Sex: Female, Male(Participants)400 mg Aripiprazole IM Depot300 mg Aripiprazole IM Depot200 mg Aripiprazole IM DepotTotal
Female74112
Male7121029
08

Study locations

7 sites
  • Otsuka Investigative Site
    Cerritos, California 90703, United States
  • Otsuka Investigative Site
    Garden Grove, California 92845, United States
  • Otsuka Investigative Site
    Glendale, California 91206, United States
  • Otsuka Investigative Site
    Paramount, California 90723, United States
  • Otsuka Investigative Site
    St. Louis, Missouri 63118, United States
  • Otsuka Investigative Site
    Willingboro, New Jersey 08046, United States
  • Otsuka Investigative Site
    Austin, Texas 78756, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2007, a primary completion of Oct 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2014, 5 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2013
First posted
Jun 6, 2013
Start
Nov 2007
Primary completionActual
Oct 2008
CompletionActual
Oct 2008
Results first posted
Jan 22, 2014
Last update
Jan 22, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01870999
Responsible party
Sponsor
First posted
Jun 6, 2013
Start date
Nov 2007
Primary completion
Oct 2008
Completion
Oct 2008
Results posted
Jan 22, 2014
Last update
Jan 22, 2014

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aripiprazole

Start the discussion